Fig. 2.

Reversal of dry eye in T1D rats following topical application of NTX-001 formulation. a Tear secretion measured 2–4 h following a single drop of new formulation (NTX-001), naltrexone dissolved in Vigamox® (Vigamox+NTX), or buffer. Values (mm) represent means ± SEM for Schirmer 1 test measurements in treated right eye. For comparison, baseline values of both normal (N) and T1D rats are included. Significantly different from T1D baseline at p < 0.05 (*) or p < 0.01 (**). b Schirmer 1 test measurements (mm) in the treated right eye (R) and untreated left eye (L) 2–4 h following a single drop of formulation (NTX-001), naltrexone dissolved in Vigamox® (Vigamox+NTX), or buffer. Values represent means ± SEM. Significantly different between right and left eyes at p < 0.05 (*) or p < 0.01 (**). n.s. = not significant. Data demonstrate that NTX-001 works quickly (within 2–4 h), restores tear secretion only in the treated eye, and is comparable in efficacy to Vigamox® + NTX treatment